Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 17 | 2025 | 540 | 3.440 |
Why?
|
| Tumor Suppressor Protein p53 | 10 | 2021 | 791 | 1.060 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 5 | 2017 | 92 | 1.050 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2024 | 819 | 0.820 |
Why?
|
| Fatty Acids | 1 | 2022 | 370 | 0.650 |
Why?
|
| N-Myc Proto-Oncogene Protein | 6 | 2022 | 65 | 0.620 |
Why?
|
| Chromatin Assembly Factor-1 | 2 | 2021 | 9 | 0.620 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2017 | 455 | 0.460 |
Why?
|
| Cell Line, Tumor | 12 | 2025 | 3751 | 0.450 |
Why?
|
| Imidazoles | 4 | 2015 | 217 | 0.440 |
Why?
|
| Piperazines | 3 | 2013 | 257 | 0.400 |
Why?
|
| Apoptosis | 5 | 2021 | 1928 | 0.360 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2021 | 2120 | 0.330 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2021 | 1006 | 0.310 |
Why?
|
| Tumor Lysis Syndrome | 2 | 2005 | 11 | 0.250 |
Why?
|
| Enzyme Inhibitors | 2 | 2021 | 607 | 0.240 |
Why?
|
| Antineoplastic Agents | 6 | 2021 | 1850 | 0.240 |
Why?
|
| Gangliosides | 1 | 2025 | 73 | 0.230 |
Why?
|
| Oncolytic Virotherapy | 1 | 2025 | 90 | 0.220 |
Why?
|
| Bacteriophages | 1 | 2025 | 85 | 0.220 |
Why?
|
| G1 Phase | 1 | 2024 | 67 | 0.210 |
Why?
|
| Animals | 16 | 2025 | 36379 | 0.210 |
Why?
|
| Mice | 14 | 2021 | 18911 | 0.200 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2021 | 18 | 0.180 |
Why?
|
| Cell Differentiation | 3 | 2021 | 2025 | 0.180 |
Why?
|
| Cyclopentanes | 1 | 2021 | 22 | 0.180 |
Why?
|
| Aurora Kinase A | 1 | 2021 | 38 | 0.180 |
Why?
|
| HCT116 Cells | 2 | 2013 | 62 | 0.170 |
Why?
|
| Gene Amplification | 1 | 2021 | 247 | 0.170 |
Why?
|
| MicroRNAs | 4 | 2018 | 950 | 0.170 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2013 | 644 | 0.160 |
Why?
|
| Oncogene Proteins | 2 | 2011 | 151 | 0.160 |
Why?
|
| Transcription Factors | 2 | 2024 | 2704 | 0.160 |
Why?
|
| Circulating MicroRNA | 1 | 2018 | 10 | 0.150 |
Why?
|
| Carcinogenesis | 1 | 2021 | 363 | 0.150 |
Why?
|
| Pyrimidines | 1 | 2021 | 417 | 0.140 |
Why?
|
| para-Aminobenzoates | 1 | 2017 | 5 | 0.140 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 745 | 0.140 |
Why?
|
| Pyrrolidines | 1 | 2017 | 41 | 0.140 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 172 | 0.130 |
Why?
|
| Humans | 23 | 2025 | 133414 | 0.130 |
Why?
|
| Serum | 1 | 2016 | 46 | 0.130 |
Why?
|
| RNA, Transfer | 1 | 2016 | 76 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 610 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2015 | 15 | 0.120 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2015 | 24 | 0.120 |
Why?
|
| Proteins | 1 | 2021 | 1087 | 0.120 |
Why?
|
| Sirolimus | 1 | 2017 | 252 | 0.120 |
Why?
|
| Gene Silencing | 2 | 2013 | 247 | 0.120 |
Why?
|
| Urate Oxidase | 2 | 2005 | 17 | 0.120 |
Why?
|
| Quinolines | 1 | 2015 | 112 | 0.110 |
Why?
|
| Cell Proliferation | 2 | 2021 | 2548 | 0.110 |
Why?
|
| Mice, Nude | 4 | 2021 | 777 | 0.110 |
Why?
|
| Nuclear Proteins | 2 | 2011 | 1334 | 0.110 |
Why?
|
| Receptors, Granulocyte Colony-Stimulating Factor | 1 | 2013 | 9 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 1070 | 0.100 |
Why?
|
| Neoplasms | 3 | 2024 | 3025 | 0.100 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 1717 | 0.100 |
Why?
|
| Cluster Analysis | 1 | 2013 | 439 | 0.100 |
Why?
|
| Neurons | 1 | 2021 | 2036 | 0.090 |
Why?
|
| Zebrafish | 2 | 2025 | 419 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 225 | 0.080 |
Why?
|
| Cell Cycle | 2 | 2024 | 626 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1349 | 0.080 |
Why?
|
| Histones | 1 | 2013 | 568 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 263 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 219 | 0.080 |
Why?
|
| Transplantation, Heterologous | 3 | 2018 | 275 | 0.080 |
Why?
|
| Gene Expression Profiling | 2 | 2013 | 1918 | 0.080 |
Why?
|
| Cell Survival | 2 | 2021 | 888 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 446 | 0.070 |
Why?
|
| Disease Progression | 1 | 2013 | 2237 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 551 | 0.060 |
Why?
|
| Prognosis | 2 | 2013 | 5074 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 1313 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2006 | 239 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 1407 | 0.060 |
Why?
|
| Photosensitizing Agents | 1 | 2025 | 38 | 0.060 |
Why?
|
| Photochemotherapy | 1 | 2025 | 44 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 4779 | 0.060 |
Why?
|
| Inhibins | 2 | 2002 | 87 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2015 | 4897 | 0.060 |
Why?
|
| Hyperuricemia | 1 | 2005 | 42 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2013 | 5176 | 0.050 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2024 | 170 | 0.050 |
Why?
|
| Gonads | 1 | 2003 | 35 | 0.050 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2024 | 124 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 2021 | 1417 | 0.050 |
Why?
|
| Gonadal Disorders | 1 | 2002 | 1 | 0.050 |
Why?
|
| Puberty | 1 | 2003 | 104 | 0.050 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2002 | 60 | 0.050 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2024 | 320 | 0.050 |
Why?
|
| NEDD8 Protein | 1 | 2021 | 12 | 0.050 |
Why?
|
| ARNTL Transcription Factors | 1 | 2021 | 41 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 1437 | 0.040 |
Why?
|
| Lipogenesis | 1 | 2021 | 59 | 0.040 |
Why?
|
| Benzamides | 1 | 2021 | 125 | 0.040 |
Why?
|
| Human Growth Hormone | 1 | 2001 | 78 | 0.040 |
Why?
|
| Female | 9 | 2021 | 71463 | 0.040 |
Why?
|
| Chromatin | 1 | 2024 | 609 | 0.040 |
Why?
|
| Body Height | 1 | 2001 | 230 | 0.040 |
Why?
|
| Male | 9 | 2021 | 65692 | 0.040 |
Why?
|
| Growth Disorders | 1 | 2001 | 221 | 0.040 |
Why?
|
| Gene Editing | 1 | 2021 | 212 | 0.040 |
Why?
|
| Gene Expression | 2 | 2016 | 1614 | 0.040 |
Why?
|
| DNA | 1 | 2024 | 1674 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 1760 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2005 | 696 | 0.030 |
Why?
|
| Child | 5 | 2018 | 25734 | 0.030 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2015 | 8 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 2526 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2015 | 139 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2015 | 65 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 129 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2015 | 173 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 1384 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2015 | 203 | 0.030 |
Why?
|
| Pyridines | 1 | 2015 | 247 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 427 | 0.030 |
Why?
|
| Side-Population Cells | 1 | 2013 | 12 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2002 | 867 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 714 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2013 | 93 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 318 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 399 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 589 | 0.020 |
Why?
|
| Luteinizing Hormone | 2 | 2002 | 137 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2013 | 613 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2002 | 195 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2013 | 230 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 959 | 0.020 |
Why?
|
| Statistics, Nonparametric | 2 | 2002 | 453 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 104 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2011 | 79 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2011 | 248 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 352 | 0.020 |
Why?
|
| Adolescent | 4 | 2018 | 20505 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 616 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 1102 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 717 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2011 | 397 | 0.020 |
Why?
|
| Kidney | 1 | 2015 | 1416 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2018 | 14789 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 7160 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2009 | 1134 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 1326 | 0.020 |
Why?
|
| Testosterone | 2 | 2002 | 596 | 0.020 |
Why?
|
| Transcriptome | 1 | 2013 | 1136 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 2005 | 8586 | 0.010 |
Why?
|
| Adult | 3 | 2018 | 31787 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2002 | 3642 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 9854 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 1873 | 0.010 |
Why?
|
| Phenotype | 1 | 2013 | 4551 | 0.010 |
Why?
|
| Quebec | 1 | 2002 | 7 | 0.010 |
Why?
|
| Growth Hormone | 1 | 2001 | 150 | 0.010 |
Why?
|
| Infant, Low Birth Weight | 1 | 2001 | 176 | 0.010 |
Why?
|
| Testis | 1 | 2002 | 426 | 0.010 |
Why?
|
| Aged | 1 | 2018 | 21609 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2001 | 364 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2001 | 825 | 0.010 |
Why?
|
| Middle Aged | 1 | 2018 | 29213 | 0.010 |
Why?
|
| Infant | 1 | 2005 | 13159 | 0.000 |
Why?
|